Haemophilus influenzae (Hi) é uma bactéria Gram negativa dependente dos fatores de crescimento NAD e hemina. O sorotipo b (Hib) é causador de doenças invasivas de importância clínica. É uma bactéria anaeróbia facultativa, e se adapta em devido à versatilidade do seu arsenal metabólico e assim, sendo capaz de causar infecção em nichos com e sem oxigênio no hospedeiro. O objetivo deste trabalho foi estudar o comportamento cinético de Hib em anaerobiose, aerobiose e a interface entre as duas condições, utilizando diferentes aceptores de elétrons (fumarato, DMSO, nitrato e oxigênio). Nitrato possui o maior potencial de redução padrão, porém o nitrito gerado de sua oxidação inviabilizou o crescimento de Hib. DMSO apresentou o melhor crescimento celular em frascos agitados, frente a fumarato de sódio. Ensaios em biorreator demonstraram que em anaerobiose, com fumarato de sódio como aceptor, succinato é o metabólito principal formado. Acetato foi produzido com todos os aceptores testados, seja em anaerobiose ou aerobiose, majoritário na última condição. Lactato de sódio e glicerol foram totalmente consumidas em aerobiose e lentamente em anaerobiose, sem esgotar nenhuma das fontes de carbono. / Haemophilus influenzae (Hi) is a Gram-negative bacterium and require growth factors for its development (hemin and NAD). Serotype b (Hib) is an important human pathogen for public health. It is a facultative anaerobic bacterium, which is allowed to adapt in several host niches due to its metabolic versatility with oxygen or its absence. The aim of this work is to study the growth kinetic of Hibs in anaerobiosis and aerobiosis, in the presence of different final electron acceptors (fumarate, DMSO, nitrate and oxygen). Nitrate has the major reduction potential among the electron acceptors tested, however Hib did not growth. In the presence of DMSO, Hib has the better growth. Anaerobic essay carried out in bioreactor showed that in the presence of fumarate as electron acceptor, succinate was the major metabolite produced. Acetate was produced in the presence of all electron acceptors tested, in both conditions (anaerobiosis and aerobiosis. Lactate and glycerol were entirely consumed in aerobiosis as carbon source and in anaerobiosis, the consumption of both carbon sources were not expressive.

Objetivos: Avaliar o impacto global, direto, indireto e a tendência da duração de proteção da vacinação contra o Haemophilus influenzae tipo b (Hib), no estado de São Paulo (ESP) e no município de São Paulo (MSP), na população de 0 - 59 meses, comparando os períodos pré-vacinal (1996 - 1998) e pós-vacinal (2001 - 2009). Métodos: estudo com componente descritivo e de cunho analítico, retrospectivo. A população de estudo incluiu os menores de cinco anos residentes no ESP e no MSP. Adotou-se como definição de caso confirmado o menor de cinco anos identificado como positivo para o Hib em cultura e/ou contraimunoeletroforese e/ou látex e/ou RT-PCR, em amostra de LCR e sangue, e/ou vínculo epidemiológico. Os dados foram obtidos a partir do SINAN, SIGH-Web Instituto Adolfo Lutz e Fundação IBGE. As variáveis de estudo incluíram as demográficas, clínicas e relativas ao agente, apresentadas em séries temporais e períodos estabelecidos para parametrização e comparabilidade. O parâmetro das avaliações de impacto foi a magnitude da variação da incidência de meningite causada pelo Hib. Para cada estimativa de impacto construiu-se um Intervalo de Confiança (IC) de 95 por cento a partir do cálculo de Risco Relativo (RR). As estimativas do risco relativo (RR) e os respectivos intervalos de 95 por cento de confiança foram analisados utilizando-se o software R. Resultados: nos períodos considerados, foram descritos 1.561 casos confirmados de meningites por Hib no ESP, sendo 27,16 por cento (424/1.561) no MSP, e 80,78 por cento (1.261/1.561) dos casos foram registrados em menores de cinco anos. A maioria dos casos foi confirmada por cultura, com percentual médio de 65 por cento no ESP e 66 por cento no MSP. As taxas médias de incidência de meningites por Hib mais significativas no período pré-vacinal verificaram-se nos menores de um ano (30,56/105- ESP; 32,06/105 - MSP), considerada a faixa etária de maior risco de adoecimento. Após a introdução da vacina contra o Hib em 1999 (menores de dois anos), as taxas de incidência de meningites por Hib declinaram de forma sustentável nos períodos subsequentes analisados. A incidência de meningite por Hib durante o período pós-vacinal variou de 4,02/105- 1,68/105 nos menores de um ano, no ESP e MSP respectivamente e, de forma similar, de 1,43/105 1,01/105 nos menores de cinco anos. Nos menores de 7 - 23 meses (impacto direto), o percentual de redução foi de 95,11 por cento [66,43 - 99,29] no ESP e 95,91 por cento [70,63 - 99,43] no MSP. O impacto global observado nos menores de cinco anos foi 88,19 por cento [26,58 - 98,10] no ESP e 91,06 por cento [33,99 - 98,79] no MSP. Os dados de vigilância mostram que os casos de meningites por Hib continuam ocorrendo, porém em níveis baixos, ao longo de 10 anos após a introdução do esquema de três doses primárias da vacina conjugada específica. Conclusão: a partir deste racional pode-se inferir a utilidade prática e econômica a favor desta modalidade programática adotada no território paulista, com a evidência de redução relativa de meningites por Hib. / Objectives: To evaluate global impact, direct and indirect, as well as the tendency of the duration of vaccine protection against Haemophilus influenzae type b (Hib) in the state of São Paulo (ESP) and in the city of São Paulo (MSP), amongst the population between 0-59 months of age during the periods pre-vaccine (1996-1998) and post vaccine (2001-2009). Methods: a retrospective study with a descriptive component and with analytic venue. Studied population included children under five years old, dwelling in ESP and MSP. Criteria adopted as definition of confirmed case was child under five years of age identified as positive for Hib in culture and/or counterimmunelectroforesis and/or latex and/or RT/PCR, in LCR sample and blood. and/or epidemiologic link. Data were obtained from the SINAN, SIGH-Web Instituto Adolfo Lutz and IBGE Foundation. Variables under study included socio-demographic and clinical ones, and those related to the agent; they were presented in temporal series and periods established in order to allow parametric and comparison. Impact evaluation was established upon the variation of incidence magnitude of meningitis caused by Hib. For each impact estimate a Confidence Interval (IC) of 95 per cent from the calculus of Relative Risk (RR). Estimates of relative risk (RR) and the respective intervals of 95 per cent confidence were analyzed employing the R software. Results: During the analyzed periods 1561 confirmed cases of meningitis caused by Hib were described in the state of São Paulo, 27.16 per cent of which (424/1561) in MSP; 80.78 per cent (1261/1561) of the registered cases occurred in children under five years of age. The majority of the cases were confirmed by culture, with an average percentage of 65 per cent in ESP and 66 per cent in MSP. More significant average rates of meningitis per Hib during the pre-vaccine period were registered in children under one year of age (30.56/105- ESP; 32.06/105 - MSP), considered the bracket under higher risk of disease. After the introduction of the vaccine against Hib, in 1999 (for children under two years of age), the rates of meningitis incidence per Hib decreased in sustainable fashion for the subsequent periods analyzed. The incidence of meningitis per Hib during the post vaccine period varied from 4.02/105 - 1.68/105 for children under one year old, in ESP and MSP, respectively and, in similar way, from 1.43/105 to 1.01/105 for those under five years old. For children between 7-23 months old (direct impact), the percentage of reduction was of 95.11 per cent [66.43 - 99.29] in ESP and 95.91 per cent [70.63 - 99.43] in MSP, whereas the global impact observed in children under five years old was 88.19 per cent [26.58 - 98.10] in ESP and 91.06 per cent [33.99 98.79] in MSP. Surveillance data show that cases of meningitis by Hib continue to occur but in low levels along 10 years after the introduction of the three doses primary scheme of administration of the specific conjugated vaccine. Conclusion: from this rationale, it is possible to infer the practical and economic utility favoring this programmatic modality adopted in São Paulo, with the evidence of the relative reduction of meningitis caused by Hib.

Made available in DSpace on 2014-07-29T15:30:37Z (GMT). No. of bitstreams: 1 Camila Xavier de Carvalho_dissertacao.pdf: 504724 bytes, checksum: a41997b1490987005878aa95bc646e53 (MD5) Previous issue date: 2010-03-19 / Haemophilus influenzae (Hi) causes infection in children, and is presented in two ways: with six encapsulated serotypes a-f and non-encapsulated or nontypeable (NTHi). Capsulated strains are responsible for a variety of invasive diseases, with meningitis being the most frequent. Nontypeable strains are responsible for respiratory tract infections and acute otitis media in children under 24 months. Children who attend day care centers have increased risk of developing otitis media when colonized with NTHi. Our goal was to describe the prevalence of colonization by Hi and risk factors associated with carrier status in children attending day care centers. Nasopharyngeal swabs collected from 1192 healthy children under five years of age who attended one of 62 daycare centers in Goiânia - Goiás, Brazil were analyzed. The samples were placed on chocolate agar plates and incubated in an atmosphere containing 5% CO2 at 37 ° C overnight. Hi were identified according with colony morphology in culture, Gram staining, and their requirement for V (hemin) and X (NAD) factors. Capsular typing and the presence of the genes TEM1 and ROB1 for resistance to β-lactams were evaluated by PCR. Differences between proportions and means were tested using Chi-square and Student's t test, respectively. Estimates of relative risk (odds ratio) were evaluated by univariate and multivariate logistic regression, p values less than 5% were considered statistically significant. The prevalence of colonization among the 1192 children was 32.1% and 23.3% for HiNT and 8.8% for encapsulated strains. The prevalence of strains carrying the gene TEM1 was 38.4%. Among HiNT strains the prevalence of TEM1 gene was 43.2%. Previous hospitalization of children in the last 6 months was independently associated with the risk carrier by H. influenzae typeable. The data described in this study will aid investigation on the impact of the 10-valent pneumococcal vaccine (PHiD-CV) introduction. / Haemophilus influenzae (Hi) é uma das espécies de bactéria que causa infecção em crianças, e se apresenta sob duas formas: capsulados com seis sorotipos de a-f e não capsulados ou não tipáveis (HiNT). Cepas capsuladas são responsáveis por uma variedade de doenças invasivas, sendo a meningite a mais freqüente. As cepas não capsuladas ou não tipáveis são responsáveis por infecções do trato respiratório e otite média aguda em menores de 24 meses. As crianças que frequentam creches têm risco aumentado de desenvolverem otite média quando colonizadas por HiNT. Nosso objetivo foi descrever a prevalência de colonização por Hi e fatores de risco associados ao estado de portador em crianças atendidas em creches. Foram analisados swabs de nasofaringe coletados de 1192 crianças saudáveis menores de cinco anos de idade que frequentavam uma das 62 creches de Goiânia - Goiás, Brasil. As amostras foram semeadas em placas de ágar chocolate e incubadas em atmosfera contendo 5% de CO2 a 37°C durante a noite. Os Hi foram identifiados de acordo com a morfologia da colônia em meio de cultura, coloração de Gram e a exigência dos fatores V (hemina) e X (NAD). A tipagem capsular assim como a presença dos genes TEM1 e ROB1 para resistência a β-lactâmicos foi avaliada pela PCR. Diferenças de proporção e de média foram avaliadas pelo teste do Chi-quadrado e teste t de student, respectivamente. Estimativas de risco relativo (odds ratio) foram avaliadas por regressão logística uni e multivariada, valores de p menores que 5%, foram considerados estatisticamente significantes. A prevalência de colonização entre as 1192 crianças foi de 32,1% sendo 23,3% para HiNT e 8,8% para cepas capsuladas. A prevalência de cepas portadoras do gene TEM1 foi de 38,4%. Dentre os HiNT a prevalência de cepas portadoras do gene TEM1 foi de 43,2%. Internação prévia da criança nos últimos 6 meses esteve independentemente associado ao risco de portador por H. influenzae tipável. Os dados obtidos neste estudo poderão subsidiar o impacto da introdução da vacina pneumocócica decavalente PHiD-CV.

Submitted by Priscila Nascimento (pnascimento@icict.fiocruz.br) on 2012-11-08T17:19:50Z No. of bitstreams: 1 01d.pdf: 1587828 bytes, checksum: 1a8694d38c20b5c410d6e957fd6a2575 (MD5) / Made available in DSpace on 2012-11-08T17:19:50Z (GMT). No. of bitstreams: 1 01d.pdf: 1587828 bytes, checksum: 1a8694d38c20b5c410d6e957fd6a2575 (MD5) Previous issue date: 2005-06 / Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil. / O objetivo deste trabalho foi aprimorar a qualidadeanalítica do laboratório de Controle Físico-Químico, LAFIQ, de Bio - Manguinhosatravés da implantação de ferramentas que permitam avaliar o desempenho dos resultados do laboratório e criar um modelo de controle. Foram estudados dois métodosde análise: determinação do conteúdo de polissacarídeo na vacina contra Haemophillus influenzaetipo B – Hib que corresponde a categoria de método tipo I, conforme Farmacopéia Americana e da condutividade em água para injetáveis correspondente a categoria de método tipo III. Os parâmetros de validação e adequação dos dois métodos foram estudados e cartas controle foram construídas utilizando os dados das análises de amostras referência realizadas por diversos analistas em dias diferentes. Com parâmetros calculados a partir destas cartas foi possível avaliar quão correto é um resultado comparado ao valor desejado, representado pelo valor da grandeza que está sendo medido. O parâmetro desvio-padrão, e o correspondente intervalo de confiança foram utilizados para medir a dispersão dos resultados através do cálculo das incertezas das medições. Para o método tipo I as estimativas das incertezas padrão combinada e expandida foram u = 0,50 µg / mL e U = 1,00 µg / mL, respectivamente. Foram considerados os parâmetros Reprodutibilidade, a concentração da solução de trabalho, do volume, da pureza do reagente, e da massa, como os que mais contribuírampara a incerteza desta categoria de método. Para o método tipo III foram encontradasas incertezas u = 0,03 µS / cm e U = 0,06 µS / cm, como incertezas padrão combinada e padrão expandida. Os fatores que mais contribuíram na incerteza deste método foram os relacionados a qualificação / calibração do equipamento, a estabilidade da amostra e a precisão do procedimento dos analistas. O uso destes recursos estatísticos desenvolvidos e estudados na presente dissertação levarão ao aprimoramento do controle da qualidade dos imunobiológicos garantindo a qualidade do trabalho dos analistas e a maior confiabilidade dos resultados fornecidos pelo LAFIQ. / The objective of this work was to improve the quality of the Bio-Manguinhos’ Laboratory of Physico-Chemical Quality Control using tools that allow to evaluate the analytical performance. The work was carried out studying two analytical methodologies: determination of the content of polysaccharide in Haemophillus influenzaetype b vaccine, that is type I according to American Pharmacopeia’s and conductivity measurement in injectable waters, type III. In thisstudy it was suggested a model that allows to guarantee the quality of results emitted by the Control Laboratory. The validation of the chosen methods and the construction of chart controls were made by evaluating the validation parameters, data for reference sample and estimating the uncertainty of the measurements. This last one is considered the quantified attribute that allows estimating if the result is correct comparedto the certified value. The uncertainty corresponds to the range of the established confidence that means the dispersion of the results. All these statistics tools will improve the implementation of a Quality System. For the method type I the uncertainty standard and expanded were u = 0,50 µg / mL and U = 1,00 µg / mL, respectively. The calculations of themeasurement uncertainty were performed considering the follow sources: Reproducibility, concentration of the standard solutions, volume, purity of reagent, and mass. Forthe method type III, the values were u = 0,02 µS/cm and U = 0,06 µS/cm. The parameters that contributed to the uncertainty of this method were: the behavior of the sample, the qualification and performance of equipment used and the stability of water samples. For both studied analytical methods the main contribution for the analytical results uncertainties was the precision of the analytical procedures. The use of these statistic tools willimprove the confidence on the analytical results from the LAFIQ.

Submitted by Priscila Nascimento (pnascimento@icict.fiocruz.br) on 2012-11-09T17:20:22Z No. of bitstreams: 1 darcy-akemi-hokama.pdf: 626817 bytes, checksum: 700e602e893be0cfb2141252bf9c68b7 (MD5) / Made available in DSpace on 2012-11-09T17:20:22Z (GMT). No. of bitstreams: 1 darcy-akemi-hokama.pdf: 626817 bytes, checksum: 700e602e893be0cfb2141252bf9c68b7 (MD5) Previous issue date: 2005-09 / Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil. / O objetivo deste trabalho foi a avaliação das melhorias alcançadas no Sistema de Controle de Qualidade de Vacinas produzidas em Bio-Manguinhos, abrangendo o período de 1999 a 2004. Analisamos que uma transferência de tecnologia bem sucedida, como a da vacina contra Haemophilus influenzae(Hib) produzida pela GlaxoSmith-Kline, Bélgica, proporcionou avanços significativos em qualidade. Vários fatoresestudados, como: melhoria no cumprimento às normas de Boas Práticas de Produção e Controle vigentes; o papel do Controle de Qualidade na absorção de tecnologia; investimento em equipamentos analíticos de última geração; captação, capacitação e treinamento de recursos humanos. Os resultados mostraram os altos índices de reprovação no processo produtivo de vacinas durante o ano de 1997, período em que as perdas chegaram a atingir até 23%. As melhorias implementadas nas áreas produtivas e de controle de qualidade, implicaram no aumento significativo do rendimento na produção das vacinas, evidenciado pelas perdas estimadas em apenas 1-3%, durante o período de 1999 a 2004 (exceto em 2000). Avaliamos também que os incrementos no sistema da qualidade não podem ser sustentados, caso não sejam adotadas outras ações essenciais, como a qualificação de fornecedores, uma dificuldade relacionada à complexidade para se adquirir produtos de qualidade, os quais podem estar envolvidos direta ou indiretamente na produção de vacinas. Desta forma, propomos a implementação de um Programa de Qualificação de Fornecedores para Bio-Manguinhos, com o objetivo de se minimizar um fator intrincado na aquisição de materiais e serviços confiáveis e, sobretudo, que garantam a qualidade no processo de fabricação de seus produtos (Vacinas, Biofármacos e Reativos para Diagnóstico). / The current work aimed to evaluate the improvementsoccurred in the Vaccine Quality Control System produced by Bio-Manguinhos from year1999 to 2004. Succeeded technology transfer against Haemophilus influenzatype B (Hib) from GlaxoSmith-Kline, Belgium, has got many improvements on quality system. Various factors were analyzed such as: improvement to meet current Good Manufacturing Practices and Control following procedures; role of Quality Control in technology absorption; investment in new-generation analytical equipments, upgrade and human resources.Results show that after improvement in the system , lost vaccine production that were as high as 23% in 1997, lowered to a range of 1~3% between 1999~2004 (except in 2000), concomitant to enhancement in production mass, what is a very substantial change. Improvements in Quality Control System were not sustainable without observing, for instance, buyingfrom qualified suppliers, one of the actual problems for obtaining proper quality products thatrelate directly or indirectly to vaccine production. From these analyzes we propose to implement Supplier Qualification Program to minimize a serious problem concerning safety material and services (Vaccines, Biopharmaceuticals and Diagnosis Reactives).

Haemophilus influenzae b (Hib) é uma bactéria patogênica causadora de pneumonia e meningite. Sua cápsula polissacarídica (PRP) é considerada como principal fator de virulência e utilizada como antígeno vacinal. Hib é fastidioso e requer micronutrientes para seu desenvolvimento. A finalidade deste trabalho é estabelecer o meio quimicamente definido para desenvolvimento de Hib e produção de PRP. Inicialmente, definiu-se um meio a partir de dados da literatura. Este meio foi estudado através do delineamento de Plackett-Burman de 44 ensaios, obtendo-se valores máximos de DO540nm de 5,0 UA, e 227,7 mg/L de PRP. A análise estatística revelou que EDTA, NH4Cl, Cys e PVA podem ser removidos do meio sem impactar os parâmetros estudados e que Glm, Hipoxantina, Inosina, Tiamina, Hemina e Tween 80 apresentam efeito significativo positivo para produção de PRP. Analisando os meios estudados, foi possível verificar que a composição do E44 possibilitou produzir o PRP a US$ 16,50/g, sendo considerado o meio quimicamente definido estabelecido neste trabalho. / Haemophilus influenzae b (Hib) is a pathogenic bacterium that causes pneumonia and meningitis. Its capsular polysaccharide (PRP) is considered as a major virulence factor and used as vaccine antigen. Hib is fastidious and requires micronutrients for its development. The purpose of this study is to establish the chemically defined medium for Hib development and PRP production. Initially, a medium was defined based in the literature. This medium was studied by the Plackett-Burman design of 44 trials, achieving maximum values of DO540nm of 5.0 AU and 227.7 mg / L of PRP. Statistical analysis revealed that EDTA, NH4Cl, Cys and PVA can be removed from the medium without impacting the parameters studied and Glm, Hypoxanthine, Inosine, Thiamine, Tween 80 and Hemin exhibit significant positive effect on the PRP production. Analyzing the studied media, it was possible to verify that the composition of E44 enabled to produce PRP to $ 16.50/g, being considered the chemically defined medium established in this work.

Introdução: O Haemophilus influenzae type b (Hib) é a primeira maior causa de meningites e pneumonias provocadas por bactérias encapsuladas. Trabalhos revelam que anticorpos maternos, séricos e secretores, podem proteger recém nascidos (RN) destes patógenos encapsulados e contribuem para a maturação do sistema imune do infante. Objetivo: O presente estudo teve como objetivo investigar a transferência materno-infantil de anticorpos anti-Hib em mães vacinadas e que não receberam a vacina anti-Hib. Materiais e Métodos: Nós avaliamos 29 mulheres saudáveis, das quais 13 foram vacinadas e 16 não receberam a vacina ActHib®. Destas mães foram obtidas amostras de sangue periférico e do cordão umbilical, colostro e leite, sendo determinadas as imunoglobulinas totais (lgG e IgA) e suas subclasses (IgG1 e 2) por Imunodifusão Radial Quantitativa (IDR) e nefelometria. A concentração de anticorpos IgG, as subclasses (lgG1 e 2) e IgA anti-Hib foram analisados por ensaio imunoenzimático (ELlSA), também utilizado para determinar a avidez dos anticorpos IgG e IgA anti-Hib. Avaliação qualitativa destes anticorpos foi realizada a partir de ensaios de immunoblotting (IB). Resultados: As amostras maternas de mães vacinadas não apresentaram diferenças quantitativas de imunoglobulinas secretoras (lgA), séricas (lgG) e suas subclasses (lgG1 e 2) totais, comparadas às amostras de mães que não receberam a vacina anti-Hib. O grupo vacinado mostrou maior concentração e avidez de anticorpos específicos para o Hib quando relacionados ao grupo de mães não vacinado. Os soros de cordões umbilicais de mães imunizadas apresentaram menor taxa de passagem transplacentária que os cordões de mães não vacinadas. Em ambos os grupos, as amostras de colostro apresentaram maior concentração de imunoglobulinas totais e específicas para o Hib que as amostras de leite. O 18 revelou o mesmo padrão de reconhecimento antigênico para o Hib entre as amostras maternas, nas duas populações. Conclusão: Os resultados revelaram que o perfil de resposta humoral de mães vacinadas pode proteger mais o infante que as mães não vacinadas, pois o primeiro grupo transferiu maior quantidade de anlicorpos com melhor avidez para a criança, conferindo proteção eficaz com relação às doenças causadas por Hib. / Background: Haemophilus influenzae, type b (Hib) has been one of the major causes of bacterial meningitis and pneumonia. Recent works show that maternal, seric and secretory antibodies, may protect the newborn and contribute the maturation of the infant immune system. Objective: The present study has as aim to investigates the maternal-infantile transfer of anti-Hib antibodies in immunized and not immunized mothers\' with anti-Hib vaccine. Material and Methods: We evaluated 29 healthy women, from whitch 13 mothers were immunized and 16 not immunized mothers with the ActHib® vaccine. From these mothers it were obtained peripheric and cord serum, colostrum and milk samples, the total immunoglobulin (IgG and IgA) and its subclass (lgG1 and IgG2) was determined by Quantitative Radial Immunodiffusion (IDR) and nephelometry. The concentration of anti-Hib IgG, subclass (lgG1 IgG2) and IgA antibodies were analyzed by immunoenzymatic assay (ELlSA), it also were utilized to determine the antibodies avidities\'. Qualitative evaluation these antibodies were determined by Immunoblotting assays (IB). Results: The results didn\'t show difference between maternal samples of the immunized and not immunized mothers in the concentration of the total secretory and seric imunoglobulins as well as its total immunoglobulins subclasses. The immunized set showed higher avidity and anti-Hib antibody levels comparing to the non-immunized mother sets. The umbilical cord serums\' from immunized mothers revealed lower rate of placental transfer than the cord serum of not immunized mothers. In both sets, the colostrum sample showed higher antibody levels comparing to the milk samples. IB revealed the same recognition pattern of Hib antigens between mother and cord serum IgG and colostrum and milk IgA, in both populations. Conclusion: The results shows that the antibodies profile response of the immunized mother can protect more the infant than the not immunized mother, because the first set transported higher quantity of antibodies with better avidity for the children, these antibodies confere an efficient protection to infections provoked by Hib.

Haemophilus influenzae tipo b é uma bactéria Gram-negativa, patogênica causadora de meningites em crianças. A cápsula polissacarídica (PSb) é o principal fator de virulência e é usado como antígeno vacinal. O método clássico de purificação do PSb envolve várias etapas de precipitação com etanol, fenol e detergente catiônico (inflamável, corrosivo e tóxico), e etapas de ultracentrifugação. O objetivo deste estudo foi substituir total ou parcial as precipitações e/ou uso das centrífugas por cromatografia, digestão enzimática, microfiltração e ultrafiltração tangencial. As cromatografias de troca iônica e de filtração em gel não apresentaram boas purificações, entretanto a hidrofóbica pode eliminar as proteínas contaminantes. As precipitações com etanol foram necessárias para obter a pureza requerida. O etanol de alguma forma favoreceu a ação enzimática e facilitou a posterior ultrafiltração. A separação com etanol em fibra-oca de microfiltração tangencial mostrou melhores purificações do que a centrifugação, mas com uso repetido verificou-se redução na eficiência. / Haemophilus influenzae type b is Gram-negative pathogenic bacterium cause meningitis in children. The capsular polysaccharide (PSb) is the main virulence factor and it is used as vaccine antigen. The classical PSb purification process includes ethanol, phenol and cationic detergent precipitations (explosion prone, corrosive, toxic) and ultracentrifugation steps. The aim of this work was to replace total or partial ethanol precipitations steps and/or elimination of centrifugation by chromatography methods, enzymatic digestion and ultrafiltration (UF) or microfiltration. The results have showed that ion exchange chromatography and gel filtration did not result in good purification, however the hydrophobic can be used for proteins elimination. The ethanol precipitation steps are necessary to achieve the required purity of PSb. In some way ethanol contributed for enzymes action and further improvements in the UF. The ethanol separation with hollow fiber microfiltration exhibited better purification than centrifugation, but after some uses the efficiency has reduced.

Ma, Hok Lun. / Thesis submitted in: December 2008. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2009. / Includes bibliographical references (leaves 233-273). / Abstracts in English and Chinese. / Abstract --- p.i / Abstract (Chinese version) --- p.v / Tables of contents --- p.vi / Acknowledgement --- p.xvi / List of figures --- p.xvii / List of tables --- p.xxi / List of abbreviations and symbols --- p.xxviii / Chapter Chapter 1 --- Introduction --- p.1 / Chapter 1.1 --- Respiratory illnesses in children --- p.1 / Chapter 1.1.1 --- Worldwide burden of childhood pneumonia --- p.1 / Chapter 1.1.2 --- Further mortality related to childhood pneumonia --- p.4 / Chapter 1.2 --- Etiology agent of childhood respiratory illnesses --- p.5 / Chapter 1.2.1 --- Difficulties in determining etiological agent --- p.5 / Chapter 1.2.2 --- Overall situation of etiological agents in childhood pneumonia --- p.6 / Chapter 1.2.3 --- Relationship between age and pathogens --- p.9 / Chapter 1.2.4 --- "Relationship between serotypes, carriage and invasiveness" --- p.11 / Chapter 1.2.4.1 --- Carriage and Invasiveness --- p.12 / Chapter 1.2.4.2.1 --- Carriage of S. pneumoniae and H. influenzae in children in Hong Kong --- p.12 / Chapter 1.2.4.2.2 --- "Serotypes, carriage and invasiveness in S. pneumoniae" --- p.14 / Chapter 1.2.4.2.3 --- "Serotypes, carriage and invasiveness in H. influenzae" --- p.17 / Chapter 1.3 --- Epidemiology of antibiotic-resistant pathogens --- p.18 / Chapter 1.3.1 --- Molecular typing methods --- p.18 / Chapter 1.3.2 --- Spread of antibiotic-resistant pathogens --- p.20 / Chapter 1.3.2.1 --- Spread of antibiotic-resistant S. pneumoniae --- p.26 / Chapter 1.3.2.1.1 --- Spread of penicillin-resistant S. pneumoniae --- p.26 / Chapter 1.3.2.1.1.1 --- Spread of Spanish-23F-1 --- p.27 / Chapter 1.3.2.1.1.2 --- Spread of Spanish-6B-2 --- p.28 / Chapter 1.3.2.1.1.3 --- Spread of antibiotic-resistant S. pneumoniae clones in Hong Kong --- p.28 / Chapter 1.3.2.1.2 --- Spread of cephalosporin-resistant S. pneumoniae --- p.29 / Chapter 1.3.2.1.3 --- Spread of macrolide-resistant S. pneumoniae --- p.30 / Chapter 1.3.2.1.4 --- Spread of fluoroquinolone-resistant S. pneumoniae --- p.31 / Chapter 1.3.2.2 --- Spread of antibiotic-resistant H. influenzae --- p.32 / Chapter 1.3.2.2.1 --- Spread of β-lactam-resistant H. influenzae --- p.32 / Chapter 1.3.2.2.2 --- Spread of macrolide-resistant H. influenzae --- p.33 / Chapter 1.3.2.2.3 --- Spread of fluoroquinolone-resistant H. influenzae --- p.34 / Chapter 1.4 --- Mechanism of antibiotic-resistance in respiratory pathogens --- p.36 / Chapter 1.4.1 --- Mechanism of antibiotic-resistance in S. pneumoniae --- p.37 / Chapter 1.4.1.1 --- Mechanism of penicillin- and cephalosporin-resistance in S. pneumoniae --- p.37 / Chapter 1.4.1.1.1 --- Penicillin-binding protein (PBP)-mediated mechanism --- p.37 / Chapter 1.4.1.1.2 --- PBP-independent mechanisms --- p.49 / Chapter 1.4.1.1.2.1 --- "Murine peptide branching genes, murMN operon" --- p.49 / Chapter 1.4.1.1.2.2 --- "Two-component system, CiaRH" --- p.50 / Chapter 1.4.1.1.2.3 --- "Putative glycosyltransferase, CpoA" --- p.52 / Chapter 1.4.1.1.3 --- RNA and protein expression studies on S. pneumoniae for β-lactam-resistance --- p.52 / Chapter 1.4.1.1.3.1 --- RNA expression in penicillin-sensitive S. pneumoniae --- p.53 / Chapter 1.4.1.1.3.2 --- Protein expression in penicillin-resistant S. pneumoniae --- p.53 / Chapter 1.4.1.2 --- Mechanism of macrolide- and lincosamide- resistance in S. pneumoniae --- p.54 / Chapter 1.4.1.3 --- Mechanism of tetracycline-resistance in S. pneumoniae --- p.55 / Chapter 1.4.1.4 --- Mechanism of fluoroquinolone-resistance in S. pneumoniae --- p.55 / Chapter 1.4.2 --- Mechanism of antibiotic-resistant in H. influenzae --- p.56 / Chapter 1.4.2.1 --- Mechanism of β-lactam-resistance in H. influenzae --- p.56 / Chapter 1.4.2.1.1 --- β-lactamase-producing H. influenzae --- p.56 / Chapter 1.4.2.1.2 --- β-lactamase-negative ampicillin-resistant (BLNAR) H. influenzae --- p.58 / Chapter 1.4.2.1.2.1 --- Relationship between amino acid substitutions in PBP3 and β-lactam- resistance --- p.58 / Chapter 1.4.2.1.2.2 --- Relationship between amino acid substitutions in AcrR and β-lactam-resistance --- p.60 / Chapter 1.4.2.2 --- Mechanism of macrolide-resistance in H. influenzae --- p.61 / Chapter 1.4.2.3 --- Mechanism of fluoroquinolone-resistance in H. influenzae --- p.64 / Chapter 1.5 --- Impact of vaccination --- p.65 / Chapter 1.5.1 --- H. influenzae type b vaccination --- p.65 / Chapter 1.5.1.1 --- Efficacy of Hib conjugate vaccine --- p.66 / Chapter 1.5.1.2 --- Herd immunity related to Hib conjugate vaccine --- p.66 / Chapter 1.5.2 --- Pneumococcal vaccination --- p.66 / Chapter 1.5.2.1 --- Vaccine efficacy and herd immunity of pneumococcal vaccines --- p.67 / Chapter 1.5.2.2 --- Development of conjugate vaccines with higher valency --- p.67 / Chapter 1.5.2.3 --- Serotype replacement --- p.67 / Chapter 1.5.2.4 --- Development of pneumococcal vaccines with new targets --- p.69 / Chapter 1.6 --- Objectives of this study --- p.70 / Chapter Chapter 2 --- Materials and methods --- p.72 / Chapter 2.1 --- Collection and Identification of microorganisms --- p.72 / Chapter 2.1.1 --- Collection of S. pneumoniae and H. influenzae --- p.72 / Chapter 2.1.2 --- Identification of S. pneumoniae and H. influenzae --- p.73 / Chapter 2.2 --- Serotyping of S. pneumoniae and H. influenzae --- p.74 / Chapter 2.2.1 --- Serotyping by polymerase chain reaction (PCR) --- p.74 / Chapter 2.2.1.1 --- Preparation of crude DNA extract --- p.74 / Chapter 2.2.1.2 --- Screening for common serotypes by multiplex PCR --- p.74 / Chapter 2.2.1.3 --- Composition of PCR Mix --- p.77 / Chapter 2.2.1.4 --- Serotyping PCR conditions --- p.81 / Chapter 2.2.1.5 --- Gel Electrophoresis --- p.81 / Chapter 2.2.2 --- Serotyping by serum agglutination --- p.82 / Chapter 2.3 --- Antimicrobial susceptibility testing --- p.83 / Chapter 2.4 --- Clonal analysis of penicillin- and cephalosporin-resistant S. pneumoniae --- p.87 / Chapter 2.4.1 --- Pulsed-field Gel Electrophoresis (PFGE) --- p.87 / Chapter 2.4.1.1 --- Preparation of agarose plugs for PFGE --- p.87 / Chapter 2.4.1.2 --- Lysis of bacteria in agarose plugs --- p.89 / Chapter 2.4.1.3 --- Digestion of chromosomal DNA by restriction enzyme --- p.89 / Chapter 2.4.2 --- Multi-locus sequence typing (MLST) --- p.90 / Chapter 2.4.2.1 --- PCR amplification of house-keeping genes in MLST --- p.90 / Chapter 2.4.2.1.1 --- Preparation of DNA from agarose plugs --- p.92 / Chapter 2.4.2.1.2 --- Composition of PCR Mix --- p.92 / Chapter 2.4.2.1.3 --- MLST PCR conditions --- p.92 / Chapter 2.4.2.1.4 --- Gel Electrophoresis of MLST PCR products --- p.92 / Chapter 2.4.2.1.5 --- MLST PCR products purification --- p.93 / Chapter 2.4.2.2 --- Sequencing of housekeeping genes in MLST --- p.93 / Chapter 2.4.2.3 --- Sequencing analysis and sequence type (ST) determination in MLST --- p.94 / Chapter 2.4.3 --- Extended panel of antibiotic susceptibility testing on S. pneumoniae with known STs --- p.94 / Chapter 2.5 --- Analysis on potential penicillin- and cephalosporin-resistance mechanisms in S. pneumoniae --- p.96 / Chapter 2.5.1 --- Sequencing of potnetial penicillin- and cephalosporin- resistance determinants in S. pneumoniae --- p.96 / Chapter 2.5.1.1 --- Primer design of penicillin-binding protein (PBP) genes --- p.96 / Chapter 2.5.1.2 --- Primer design of non-PBP resistance determinants --- p.100 / Chapter 2.5.1.3 --- PCR amplification and sequencing of resistant determinants --- p.100 / Chapter 2.5.1.4 --- Sequence analysis --- p.100 / Chapter 2.5.2 --- Study on efflux mechanism of S. pneumoniae --- p.103 / Chapter 2.5.2.1 --- Modification of macrodilution for efflux assay --- p.103 / Chapter 2.5.2.2 --- Cefotaxime MIC determination with efflux inhibitors --- p.104 / Chapter 2.5.2.3 --- Determination of appropriate CCCP concentration --- p.105 / Chapter 2.5.2.4 --- Growth curve with efflux inhibitor --- p.105 / Chapter 2.5.3 --- Heteroresistance assay of S. pneumoniae --- p.106 / Chapter 2.5.4 --- "RNA expression study on penicillin- and cefotaxime-resistance determinants (pbp2x, pbpla and pbp2a) of S. pneumoniae" --- p.107 / Chapter 2.5.4.1 --- Growth of S. pneumoniae for RNA extraction --- p.107 / Chapter 2.5.4.2 --- RNA extraction and DNase digestion --- p.107 / Chapter 2.5.4.3 --- cDNA synthesis and real-time PCR --- p.108 / Chapter 2.6 --- Analysis on cephalosporin- and macrolide-resistance mechanisms in H. influenzae --- p.111 / Chapter 2.6.1 --- β-lactamase production of H. influenzae --- p.111 / Chapter 2.6.1.1 --- Nitrocefin Hydrolysis --- p.111 / Chapter 2.6.1.2 --- Screening for the presence of p-lactamase gene (blaTEM-1 and blaROB-1) by multiplex PCR --- p.111 / Chapter 2.6.2 --- PCR detection and sequencing of β-lactam- and macrolide- resistance determinants in H. influenzae --- p.113 / Chapter Chapter 3 --- Results of S. pneumoniae and H. influenzae children study --- p.116 / Chapter 3.1 --- Patient demographics of children study --- p.116 / Chapter 3.2 --- Serotype distributions --- p.117 / Chapter 3.2.1 --- Serotypes / serogroup distribution in S. pneumoniae --- p.117 / Chapter 3.2.2 --- Serotype distribution in H. influenzae children study --- p.120 / Chapter 3.3 --- Antibiotic susceptibilities and resistance antibiograms --- p.122 / Chapter 3.3.1 --- Antibiotic susceptibilities of S. pneumoniae --- p.122 / Chapter 3.3.2 --- Relationship between antibiotic resistance profiles and serotypes in S.pneumoniae --- p.126 / Chapter 3.3.3 --- Antibiotic susceptibilities of H. influenzae --- p.135 / Chapter 3.3.4 --- Antibiotic resistance profiles of H. influenzae --- p.138 / Chapter 3.4 --- Clonal analysis of penicillin- and cephalosporin-resistant S.pneumoniae --- p.139 / Chapter 3.4.1 --- Pulsed-field gel electrophoresis (PFGE) of S. pneumoniae --- p.139 / Chapter 3.4.2 --- Multi-locus sequence typing of S. pneumoniae --- p.141 / Chapter 3.5 --- Analysis of the penicillin- and cephalosporin-resistance determinants in S. pneumoniae --- p.143 / Chapter 3.5.1 --- "Sequence analysis of major pbp genes (pbp2x, pbpla and pbp2a)" --- p.143 / Chapter 3.5.2 --- "Sequence analysis of other potential penicillin- and cephalosporin- resistance determinants (pbp 1 b, pbp2b, pbp3, cpoA, ciaRH and murMN)" --- p.152 / Chapter 3.5.3 --- Sequence analysis of putative promoter sequences of pbp genes --- p.167 / Chapter 3.5.4 --- Efflux Inhibition Assay --- p.171 / Chapter 3.5.5 --- Heteroresistance Assay --- p.177 / Chapter 3.5.6 --- "RNA expression study on penicillin- and cephalosporin resistance determinants (pbp2x, pbpla and pbp2a)" --- p.179 / Chapter 3.6 --- Analysis of β-lactam-resistance determinants in H. influenzae --- p.185 / Chapter 3.6.1 --- β-lactamase production and blaTEM-1 promoter study --- p.185 / Chapter 3.6.2 --- "Sequence analysis of β-lactam-resistance determinants (ftsl, acrR genes, AcrAB-TolC efflux pump)" --- p.188 / Chapter 3.6.2.1 --- Sequence analysis offtsl --- p.188 / Chapter 3.6.2.2 --- Analysis of acrR and AcrAB-TolC efflux pump --- p.189 / Chapter 3.7 --- "Analysis of macrolide-resistance determinants in H, influenzae (AcrAB-TolC efflux pump, 23SrRNA, Ribosomal proteins L4 and L22)" --- p.199 / Chapter Chapter 4 --- Discussion on S. pneumoniae and H. influenzae children study --- p.204 / Chapter 4.1 --- Carriage rate of S. pneumoniae children collection --- p.204 / Chapter 4.2 --- Serotype distribution --- p.205 / Chapter 4.2.1 --- Serotype distribution and potential vaccine coverage in S. pneumoniae --- p.205 / Chapter 4.2.2 --- Serotype distribution in H. influenzae --- p.209 / Chapter 4.3 --- Antimicrobial resistance --- p.210 / Chapter 4.3.1 --- Antimicrobial resistance in S. pneumoniae --- p.210 / Chapter 4.3.2 --- Antimicrobial resistance in H. influenzae --- p.214 / Chapter 4.4 --- "Clonal analysis of high-level β-lactam-resistant S, pneumoniae" --- p.217 / Chapter 4.5 --- "β-lactam-resistance mechanisms in S, pneunomiae" --- p.220 / Chapter 4.6 --- Antimicrobial resistance mechanisms in H. influenzae --- p.224 / Chapter 4.6.1 --- β-lactam-resistance mechanism in β-lactamase-producing H. influenzae --- p.224 / Chapter 4.6.1.1 --- Variations in blaTEM-1 promoters in β-lactamase-producing H.influenzae --- p.224 / Chapter 4.6.1.2 --- β-lactam-resistance in β-lactamase-nonproducing H. influenzae --- p.225 / Chapter 4.6.2 --- Macrolide-resistance mechanisms in H. influenzae --- p.228 / Chapter Chapter 5 --- Conclusion and future studies --- p.230 / Chapter 5.1 --- "S, pneumoniae children study" --- p.230 / Chapter 5.2 --- H. influenzae children study --- p.231 / Chapter 5.3 --- Future studies --- p.232 / Bibliography --- p.233 / Appendix I 一 Sequence alignments and Tables --- p.274 / Appendix II 一 Materials and Methods --- p.313

Introdução: O Haemophilus influenzae type b (Hib) é a primeira maior causa de meningites e pneumonias provocadas por bactérias encapsuladas. Trabalhos revelam que anticorpos maternos, séricos e secretores, podem proteger recém nascidos (RN) destes patógenos encapsulados e contribuem para a maturação do sistema imune do infante. Objetivo: O presente estudo teve como objetivo investigar a transferência materno-infantil de anticorpos anti-Hib em mães vacinadas e que não receberam a vacina anti-Hib. Materiais e Métodos: Nós avaliamos 29 mulheres saudáveis, das quais 13 foram vacinadas e 16 não receberam a vacina ActHib®. Destas mães foram obtidas amostras de sangue periférico e do cordão umbilical, colostro e leite, sendo determinadas as imunoglobulinas totais (lgG e IgA) e suas subclasses (IgG1 e 2) por Imunodifusão Radial Quantitativa (IDR) e nefelometria. A concentração de anticorpos IgG, as subclasses (lgG1 e 2) e IgA anti-Hib foram analisados por ensaio imunoenzimático (ELlSA), também utilizado para determinar a avidez dos anticorpos IgG e IgA anti-Hib. Avaliação qualitativa destes anticorpos foi realizada a partir de ensaios de immunoblotting (IB). Resultados: As amostras maternas de mães vacinadas não apresentaram diferenças quantitativas de imunoglobulinas secretoras (lgA), séricas (lgG) e suas subclasses (lgG1 e 2) totais, comparadas às amostras de mães que não receberam a vacina anti-Hib. O grupo vacinado mostrou maior concentração e avidez de anticorpos específicos para o Hib quando relacionados ao grupo de mães não vacinado. Os soros de cordões umbilicais de mães imunizadas apresentaram menor taxa de passagem transplacentária que os cordões de mães não vacinadas. Em ambos os grupos, as amostras de colostro apresentaram maior concentração de imunoglobulinas totais e específicas para o Hib que as amostras de leite. O 18 revelou o mesmo padrão de reconhecimento antigênico para o Hib entre as amostras maternas, nas duas populações. Conclusão: Os resultados revelaram que o perfil de resposta humoral de mães vacinadas pode proteger mais o infante que as mães não vacinadas, pois o primeiro grupo transferiu maior quantidade de anlicorpos com melhor avidez para a criança, conferindo proteção eficaz com relação às doenças causadas por Hib. / Background: Haemophilus influenzae, type b (Hib) has been one of the major causes of bacterial meningitis and pneumonia. Recent works show that maternal, seric and secretory antibodies, may protect the newborn and contribute the maturation of the infant immune system. Objective: The present study has as aim to investigates the maternal-infantile transfer of anti-Hib antibodies in immunized and not immunized mothers\' with anti-Hib vaccine. Material and Methods: We evaluated 29 healthy women, from whitch 13 mothers were immunized and 16 not immunized mothers with the ActHib® vaccine. From these mothers it were obtained peripheric and cord serum, colostrum and milk samples, the total immunoglobulin (IgG and IgA) and its subclass (lgG1 and IgG2) was determined by Quantitative Radial Immunodiffusion (IDR) and nephelometry. The concentration of anti-Hib IgG, subclass (lgG1 IgG2) and IgA antibodies were analyzed by immunoenzymatic assay (ELlSA), it also were utilized to determine the antibodies avidities\'. Qualitative evaluation these antibodies were determined by Immunoblotting assays (IB). Results: The results didn\'t show difference between maternal samples of the immunized and not immunized mothers in the concentration of the total secretory and seric imunoglobulins as well as its total immunoglobulins subclasses. The immunized set showed higher avidity and anti-Hib antibody levels comparing to the non-immunized mother sets. The umbilical cord serums\' from immunized mothers revealed lower rate of placental transfer than the cord serum of not immunized mothers. In both sets, the colostrum sample showed higher antibody levels comparing to the milk samples. IB revealed the same recognition pattern of Hib antigens between mother and cord serum IgG and colostrum and milk IgA, in both populations. Conclusion: The results shows that the antibodies profile response of the immunized mother can protect more the infant than the not immunized mother, because the first set transported higher quantity of antibodies with better avidity for the children, these antibodies confere an efficient protection to infections provoked by Hib.